researchers have evolved a technology to manufacture vaccines that do not need to be refrigerated. The feat may enable additional vaccination of 10 million children every year, claim officials of the uk-based Cambridge Biostability, which will manufacture the vaccine in collaboration with Panacea Biotec, New Delhi. The vaccine will simultaneously work against diphtheria, tetanus, whopping cough, hepatitis b and a form of meningitis.

Worldwide, about two million children die every year from vaccine-preventable diseases; at the same time, up to half the vaccines get damaged because of temperature-induced changes.

The key to the new technique is encasing the active ingredients of a vaccine in a sugary coat, which preserves them even at a temperature of 60